Human Prion Diseases, Volume 153 is designed to update the reader on the latest advances and clinical aspects of prion diseases. The book is organized into five sections, including the pathophysiology of prions and a description of animal and human diseases. This is followed by detailed reports on recent advances in diagnosis strategies for the development of novel anti-prion molecules and possible designs of clinical trials in such a rare disease. An introductory chapter gives an extensive historical background of prion research, with a final chapter highlighting recent progress, and more importantly, unsolved problems. …mehr
Human Prion Diseases, Volume 153 is designed to update the reader on the latest advances and clinical aspects of prion diseases. The book is organized into five sections, including the pathophysiology of prions and a description of animal and human diseases. This is followed by detailed reports on recent advances in diagnosis strategies for the development of novel anti-prion molecules and possible designs of clinical trials in such a rare disease. An introductory chapter gives an extensive historical background of prion research, with a final chapter highlighting recent progress, and more importantly, unsolved problems.
Professor Maurizio Pocchiari is a neurologist working at the Istituto Superiore di Sanità, Rome, Italy, where chairs the Department of Neuroscience. He heads a group of neurologists, geneticists, biochemists, and statisticians working on various aspects of human and experimental prion diseases. These include studies on clinical and molecular epidemiology, diagnosis, pathogenesis, experimental therapy, biochemistry and molecular and cellular biology of the prion protein and the prion protein gene, development of new techniques for the inactivation of prions, and the analysis of risk in transmitting prions from animal-to-human or from human-to-human. Professor Pocchiari runs the Italian Creutzfeldt-Jakob disease surveillance unit since 1993 and is a member of the Coordination Committee of the European Creutzfeldt-Jakob disease Surveillance Network (EuroCJD) of the European Centre for Disease Prevention and Control (ECDC).
Inhaltsangabe
1. Historical view
Section I: Pathophysiology of prions 2. The cellular and pathological prion protein 3. Cell biology of prion infection 4. Experimental models of human prion diseases and prion strains 5. The role of the immune system in prion infection
Section II: Animal prion diseases (clinical, epidemiology, neuropathological, biochemical, biomarker, and genotypes) 6. Typical and atypical scrapie 7. Typical and atypical BSE 8. Chronic Wasting Disease
Section IV: Prion-like mechanisms in other neurodegenerative diseases 16. Prion-like mechanisms in Alzheimer 17. Prion-like mechanisms in Parkinson 18. Prion-like mechanisms in ALS
Section V: Diagnosis and treatment 19. Prion protein amplification techniques 20. Differential diagnosis with other rapid progressive dementias 21. Symptomatic treatment, care and support of CJD patients 22. Identifying therapeutic targets and treatment in model systems 23. Vaccination strategies 24. Clinical trials
Section VI: Public health issues 25. Animal diseases and the zoonotic potential 26. Safety of blood, blood derivatives and plasma-derived products 27. Safety in clinical practice 28. Concluding thoughts
Section I: Pathophysiology of prions 2. The cellular and pathological prion protein 3. Cell biology of prion infection 4. Experimental models of human prion diseases and prion strains 5. The role of the immune system in prion infection
Section II: Animal prion diseases (clinical, epidemiology, neuropathological, biochemical, biomarker, and genotypes) 6. Typical and atypical scrapie 7. Typical and atypical BSE 8. Chronic Wasting Disease
Section IV: Prion-like mechanisms in other neurodegenerative diseases 16. Prion-like mechanisms in Alzheimer 17. Prion-like mechanisms in Parkinson 18. Prion-like mechanisms in ALS
Section V: Diagnosis and treatment 19. Prion protein amplification techniques 20. Differential diagnosis with other rapid progressive dementias 21. Symptomatic treatment, care and support of CJD patients 22. Identifying therapeutic targets and treatment in model systems 23. Vaccination strategies 24. Clinical trials
Section VI: Public health issues 25. Animal diseases and the zoonotic potential 26. Safety of blood, blood derivatives and plasma-derived products 27. Safety in clinical practice 28. Concluding thoughts
Es gelten unsere Allgemeinen Geschäftsbedingungen: www.buecher.de/agb
Impressum
www.buecher.de ist ein Internetauftritt der buecher.de internetstores GmbH
Geschäftsführung: Monica Sawhney | Roland Kölbl | Günter Hilger
Sitz der Gesellschaft: Batheyer Straße 115 - 117, 58099 Hagen
Postanschrift: Bürgermeister-Wegele-Str. 12, 86167 Augsburg
Amtsgericht Hagen HRB 13257
Steuernummer: 321/5800/1497
USt-IdNr: DE450055826